|Bid||167.10 x 0|
|Ask||167.20 x 0|
|Day's Range||164.20 - 169.95|
|52 Week Range||152.05 - 265.00|
|Beta (3Y Monthly)||1.01|
|PE Ratio (TTM)||17.91|
|Earnings Date||Oct 31, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||218.00|
STOCKHOLM , Aug. 22, 2019 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) has entered into an agreement to sell a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) ...
STOCKHOLM , July 17, 2019 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces its results for the second quarter 2019. Total revenue was SEK 3,163 M (2,289), with 38 per cent revenue ...
STOCKHOLM, July 16, 2019 /PRNewswire/ -- Sobi™ has established the Sobi Scientific Innovation Awards, with a focus on the future of haemophilia care, to recognise innovation and scientific excellence in haemophilia research. Entries will be assessed by an Adjudication Committee of independent, international haemophilia experts, according to scientific credit and contribution to haemophilia, overall concept novelty, as well as the anticipated ability of the research to help liberate life for people with haemophilia. Armin Reininger, Head of Medical and Scientific Affairs at Sobi, says the aim is to focus on research that reflects a meaningful difference for patients.
STOCKHOLM, July 9, 2019 /PRNewswire/ -- Clinical study data on switching haemophilia A and B patients from on-demand treatment to extended half-life (EHL) prophylaxis showed a positive impact on clinical outcomes, with improvements in quality of life (QoL) and reduced annual bleeding rates (ABR). The results of these joint studies by Sobi™ and Sanofi were presented at ISTH 2019, the 27th Congress of the International Society on Thrombosis and Haemostasis, in Melbourne, Australia, on 7, 8 and 9 July 2019. The introduction of EHL factor replacement products has led to patients switching from standard half-life products to EHLs as well as from on-demand treatment to EHL prophylaxis.
STOCKHOLM , July 8, 2019 /PRNewswire/ -- On 17 July, at 08:00 CET , Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the second quarter 2019. Financial analysts and media are invited ...
STOCKHOLM, July 8, 2019 /PRNewswire/ -- Interim results from verITI-8, an ongoing prospective, phase 4 study evaluating the efficacy of Elocta® (efmoroctocog alfa), for first-time Immune Tolerance Induction (ITI) for people with severe haemophilia A with inhibitors were presented today. The development of inhibitors, or antibodies, to FVIII replacement therapy is one of the most serious complications for people with haemophilia, occurring in approximately 30 percent of people with severe haemophilia A during their lifetime. Eradication of inhibitors through ITI is currently the standard of care.
STOCKHOLM, July 8, 2019 /PRNewswire/ -- People with haemophilia have an increased risk of acute and chronic pain, and long-term disability, associated with bleeds. Anxiety and depression are other factors negatively affecting their quality of life. The results of the MIND study also show that people with haemophilia in Sweden have a substantially higher prescription of analgesics than the general population. A similar prescription pattern could be seen among female carriers of the genes for haemophilia, which leads to a reduced ability of the blood to clot.
Now we take one step further and show how our products can help to raise the standard of care in various situations in life, liberating life and expanding the possibilities for people with haemophilia," says Armin Reininger, Head of Medical and Scientific Affairs at Sobi. Improved Hemostasis and Joint Health over Time in a Subset of Patients who Did Not Reach Optimal Hemostatic Control in the First Year of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Therapy: Sunday 7 July, Poster # PB0234.
STOCKHOLM , June 18, 2019 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announces that new research demonstrating the effects of emapalumab in patients with macrophage activation ...
The new focus of the R&D organisation would lead to annual savings of SEK 200–300 M in 2020 to be reallocated to late-stage development. Costs of around SEK 100–200 M relating to the reorganisation and redundancies will be charged in 2019. Following today's announcement of the acquisition of emapalumab and related assets, Sobi™ (Swedish Orphan Biovitrum AB (publ) (SOBI.ST) intends to carry out a reorganisation to increase the focus of research & development resources to support its two core therapeutic areas: Haematology and Immunology.
STOCKHOLM, June 12, 2019 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (SOBI.ST) has signed an agreement to acquire, from Novimmune's shareholders, a newly established company owning emapalumab and related assets, giving Sobi access to world-class R&D capabilities in the field of Immunology. The acquisition means that the previously announced exclusive licence agreement with Novimmune will be superseded.
Sobi, an international biopharmaceutical company transforming the lives of people affected by rare diseases, announced the launch of a new video that shows the role of interferon gamma in primary hemophagocytic lymphohistiocytosis and how Gamifant® may help.
Sobi, an international biopharmaceutical company transforming the lives of people affected by rare diseases, announced the publication of data demonstrating the impact of hospitalizations due to respiratory syncytial virus (RSV) on caregivers of high-risk preterm infants in the U.S. The study, which was published in the journal Clinical Pediatrics, showed that these caregivers experienced missed work, diminished work productivity, emotional stress, disruption of family routine and financial concerns, many of which persisted at least one month following hospital discharge.
STOCKHOLM, May 14, 2019 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) is hosting a Capital Markets Day at Karolinska Institutet Biomedicum in Solna, Sweden, today. Presentations from senior management and an external expert are showcasing how Sobi is well positioned to use its rare strength to expand business in Haemophilia and Immunology. In 2018, Sobi announced both the acquisition of emapalumab from Novimmune SA and the Synagis® US franchise from AstraZeneca.
STOCKHOLM, May 10, 2019 /PRNewswire/ -- Today, Sobi™ and Sanofi will present data demonstrating that Elocta® (efmoroctocog alfa) and Alprolix® (eftrenonacog alfa) can provide perioperative haemostatic control across a wide spectrum of major and minor surgeries in subjects of all ages with severe haemophilia A and B respectively. The presentation will take place at the World Federation of Hemophilia's 16th International Musculoskeletal Congress (MSK) 10-12 May 2019, in Madrid, Spain. It is possible to minimise blood loss during surgery by treating patients with an individualised and optimal factor replacement therapy to control the haemostasis.
Sobi, an international biopharmaceutical company transforming the lives of people affected by rare diseases, announced today the publication of data demonstrating the continued burden of severe lower respiratory tract infection due to respiratory syncytial virus (RSV) in preterm infants in the U.S. The data represent the results of the SENTINEL1 study, in which 46 hospitals across the U.S. collected observational data on preterm infants born at 29-35 weeks gestation who did not receive immunoprophylaxis for RSV and were subsequently hospitalized for RSV disease during the 2014-2015 or 2015-2016 RSV seasons (roughly October through April).
STOCKHOLM , April 30, 2019 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) has appointed Amy Pott as the new Head of Sobi North America . She takes over effective today, replacing Rami Levin ...
STOCKHOLM , April 25, 2019 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces its results for the first quarter 2019. Total revenues were SEK 3,265 M (1,964), with 66 per cent revenue ...
STOCKHOLM , April 18, 2019 /PRNewswire/ - Swedish Orphan Biovitrum AB (publ) (Sobi™) has released the company's 2018 Annual and Sustainability Report. The integrated report summarises our business and ...
STOCKHOLM , April 12, 2019 /PRNewswire/ --On 25 April, at 08:00 CET , Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the fourth quarter and full year 2018. Financial analysts and ...
Sobi, an international biopharmaceutical company transforming the lives of people affected by rare diseases, presented an update on the state of newborn screening for Hereditary Tyrosinemia Type 1 (HT-1) in the United States during the Association of Public Health Laboratories’ (APHL) 2019 Newborn Screening and Genetic Testing Symposium, April 7-10 in Chicago. HT-1 is an extremely rare but treatable hereditary disorder.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Every investor in Swedish Orphan Biovitrum AB (publ) (STO:SOBI) should be aware of the most powerful shareholder groups...
Sobi, an international biopharmaceutical company transforming the lives of people affected by rare diseases, announced that investigators will present data from across its rare disease and specialty care portfolio at multiple scientific meetings this Spring.